Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001333
Filing Date
2025-05-15
Accepted
2025-05-15 16:23:12
Documents
72
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nwbo-20250331x10q.htm   iXBRL 10-Q 1868868
2 EX-31.1 nwbo-20250331xex31d1.htm EX-31.1 15043
3 EX-32.1 nwbo-20250331xex32d1.htm EX-32.1 10401
  Complete submission text file 0001410578-25-001333.txt   9585721

Data Files

Seq Description Document Type Size
4 EX-101.SCH nwbo-20250331.xsd EX-101.SCH 68329
5 EX-101.CAL nwbo-20250331_cal.xml EX-101.CAL 57505
6 EX-101.DEF nwbo-20250331_def.xml EX-101.DEF 312022
7 EX-101.LAB nwbo-20250331_lab.xml EX-101.LAB 491628
8 EX-101.PRE nwbo-20250331_pre.xml EX-101.PRE 424712
75 EXTRACTED XBRL INSTANCE DOCUMENT nwbo-20250331x10q_htm.xml XML 2077579
Mailing Address 4800 MONTGOMERY LANE SUITE 800 BETHESDA MD 20814
Business Address 4800 MONTGOMERY LANE SUITE 800 BETHESDA MD 20814 (240) 497-9024
NORTHWEST BIOTHERAPEUTICS INC (Filer) CIK: 0001072379 (see all company filings)

EIN.: 943306718 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35737 | Film No.: 25953779
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)